[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Equillium Inc (EQ)

Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,732
  • Shares Outstanding, K 63,227
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,400 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.19

Options Overview Details

View History
  • Implied Volatility 197.51% (+63.74%)
  • Historical Volatility 113.82%
  • IV Percentile 16%
  • IV Rank 9.43%
  • IV High 1,340.64% on 11/19/25
  • IV Low 78.53% on 12/18/25
  • Expected Move (DTE 27) 0.21 (9.28%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 201
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 954
  • Open Int (30-Day) 1,759
  • Expected Range 2.08 to 2.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 5
  • High Estimate $-0.04
  • Low Estimate $-0.06
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +30.48%
on 05/19/26
2.64 -13.26%
on 05/15/26
-0.04 (-1.72%)
since 04/22/26
3-Month
1.60 +43.12%
on 03/30/26
2.70 -15.19%
on 03/16/26
+0.55 (+31.61%)
since 02/20/26
52-Week
0.27 +748.15%
on 06/24/25
2.70 -15.19%
on 03/16/26
+1.89 (+478.28%)
since 05/22/25

Most Recent Stories

More News
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer...

EQ : 2.26 (+2.26%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium Announces Poster Presentations at IMMUNOLOGY2026â„¢, the Annual Meeting of the American Association of Immunologists

LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing,...

EQ : 2.26 (+2.26%)
Equillium to Participate in the 38th Annual Roth Conference

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)
Equillium Announces $35 Million Financing with RA Capital Management

Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA...

EQ : 2.26 (+2.26%)
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 2.26 (+2.26%)

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 2.54
2nd Resistance Point 2.38
1st Resistance Point 2.30
Last Price 2.26
1st Support Level 2.06
2nd Support Level 1.90
3rd Support Level 1.82

See More

52-Week High 2.70
Last Price 2.26
Fibonacci 61.8% 1.77
Fibonacci 50% 1.49
Fibonacci 38.2% 1.20
52-Week Low 0.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.